Vericel Corporation | Advanced cell therapies

Nexobrid is now approved
for use in the U.S.

Innovative Treatments

Explore our unique life-enhancing therapies

Patient Testimonials

See what people are saying about our therapies

Join Our Team

Find out about a career at Vericel

Vericel manufactures and markets two advanced cell therapy products for sports medicine and severe burn care in the United States and holds an exclusive license for North American commercial rights to NexoBrid^®, a biological orphan product approved for eschar removal of severe thermal burns. Please use the links to the right to visit our product websites and learn more about our pipeline.

Learn About the MACI Arthro Development Program

Vericel’s unique biopharma focus: Tackling unmet needs in sports medicine and burn treatment

Vericel’s unique biopharma focus: Tackling unmet needs in sports medicine and burn treatment

by Drug Discovery and Development | March 16, 2023

Vericel (Nasdaq:VCEL), a biopharma focused on sports medicine and severe burn care therapies, has a portfolio including the cartilage repair treatment MACI and the burn treatments Epicel and NexoBrid...

Vericel (VCEL) President & CEO On Sports Medicine & Severe Burn Care Therapies

Vericel (VCEL) President & CEO On Sports Medicine & Severe Burn Care Therapies

by TD Ameritrade Network | January 20, 2023

Vericel (VCEL) is a commercial-stage biopharma company that focuses on sports medicine and severe burn care therapies. President and CEO, Nick Colangelo discusses VCEL as it expects an accelerated commercial launch for arthroscopic MACI...

Vericel Shares Accelerated Launch Timeline for MACI Arthroscopic Program

Vericel Shares Accelerated Launch Timeline for MACI Arthroscopic Program

by Orthopedic Design & Technology (ODT) | January 11, 2023

Vericel Corporation, a leader in advanced therapies for the sports medicine and severe burn care markets, has announced an accelerated launch timeline for MACI arthroscopic delivery, which is now anticipated to be launched in 2024...

Vericel Shares Up 13% on Preliminary FY22 Revenue Gain, Accelerated MACI Launch

Vericel Shares Up 13% on Preliminary FY22 Revenue Gain, Accelerated MACI Launch

by MarketWatch | January 10, 2023

Shares of Vericel Corp. increased 13%, to $27, on Tuesday after the company reported preliminary full-year 2022 revenue figures and said it expects an accelerated commercial launch timeline for its MACI arthroscopic delivery program...

FDA Approves NexoBrid As Therapy For Severe Burns

FDA Approves NexoBrid As Therapy For Severe Burns

by Medical Dialogues | January 8, 2023

The US Food and Drug Administration (FDA) has approved NexoBrid (anacaulase-bcdb) as therapy for severe burns. It has potential to become the new standard of care for eschar removal in patients with deep partial- and/or full- thickness thermal burns...

FDA approves MediWound’s NexoBrid to treat thermal burns

FDA approves MediWound’s NexoBrid to treat thermal burns

by Medical Device Network | January 3, 2023

MediWound has secured approval from the US Food and Drug Administration (FDA) for its NexoBrid (anacaulase-bcdb) treatment for eliminating eschar in adults with deep partial-thickness and/or full-thickness thermal burns...

Severe Burn Therapy NexoBrid Gets FDA Approval

Severe Burn Therapy NexoBrid Gets FDA Approval

by MPR | January 3, 2023

The Food and Drug Administration (FDA) has approved NexoBrid® (anacaulase-bcdb) for eschar removal in adults with deep partial thickness and/or full thickness thermal burns...

Vericel: Aggressive Growth In 2023 (NASDAQ:VCEL)

Vericel: Aggressive Growth In 2023 (NASDAQ:VCEL)

by Seeking Alpha | January 1, 2023

In biotech investing, you should not be discouraged when seeing your stock decline while the fundamentals are boosted. That is to say, there will be periodic mismatches between the stock's intrinsic value and its true worth...

Vericel scores FDA approval for $142M burn treatment

Vericel scores FDA approval for $142M burn treatment

by Boston Business Journal | December 30, 2022

Three and a half years after licensing it from an Israeli pharma in a $142 million deal, Vericel Corporation has won FDA approval for NexoBrid, a gel designed to treat serious burns...

NASDAQ: VCEL

$28.97 0.16 (0.56%)

Day High: $29.02
Day Low: $28.04
Volume: 193423

3:00 PM on
March 24, 2023

Copyright West LLC. Minimum 15 minutes delayed.

Company Presentation

Vericel Company Presentation

Download the PDF

ESG Report

ESG Report

Download the PDF